市場調査レポート
商品コード
1076360

創薬アウトソーシングの市場規模、シェア、動向分析レポート:薬剤タイプ別(低分子、高分子)、治療領域別(呼吸器系、免疫調節)、ワークフロー別、セグメント別予測、2022~2030年版

Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Drug Type (Small, Large Molecules), By Therapeutic Area (Respiratory System, Immunomodulation), By Workflow, And Segment Forecasts, 2022 - 2030

出版日: | 発行: Grand View Research | ページ情報: 英文 137 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
創薬アウトソーシングの市場規模、シェア、動向分析レポート:薬剤タイプ別(低分子、高分子)、治療領域別(呼吸器系、免疫調節)、ワークフロー別、セグメント別予測、2022~2030年版
出版日: 2022年04月11日
発行: Grand View Research
ページ情報: 英文 137 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

創薬アウトソーシング市場の成長と動向

Grand View Research, Inc.の新しいレポートによると、世界の創薬アウトソーシング市場規模は、予測期間中にCAGR7.4%で2030年までに63億米ドルに達すると予測されています。

COVID-19の大流行により、製薬会社が脚光を浴びるようになりました。創薬はコストと時間のかかるプロセスです。このため、製薬会社やバイオテクノロジー会社は、学術機関や民間の契約研究機関(CRO)に研究活動をアウトソーシングすることを選択するよう促されています。官民のパートナーシップの高まりは創薬プロセスを加速させ、その結果、創薬のためのアウトソーシングサービスの世界の需要を増大させています。

このシナリオは、共産主義的な意味合いも含めて、今後も継続されると予想されます。慢性疾患患者の増加により、企業は寿命を延ばすための医薬品の開発を迫られています。国連によると、2015年から2020年の間に65歳になった人は、さらに17年生きられると予想されています。企業がアウトソーシングに積極的に取り組んでいる主な治療分野には、がん、循環器、抗感染症などがあります。2020年11月、アストラゼネカは、最も治療が困難ながんの研究を促進するために、最先端の腫瘍学医療センター9施設と協力しました。同社は、このネットワークのメンバーからの臨床および非臨床研究提案に資金を提供する予定です。

COVID-19のパンデミックは、創薬と開発の価値を実証しています。世界中の人々がワクチンを待っている一方で、複数の企業がCOVID-19に対抗する効果的なワクチンの開発に積極的に取り組んでいます。ファイザー社とバイオテックSE社は、このウイルスに対抗する潜在的な菌株の世界の第3相試験を経て、ワクチンの最初の承認を得ました。臨床試験については、その多くが停止している一方で、遠隔監視技術を採用することで機能しているものもあります。このように、パンデミックによって製薬業界は中心的な舞台となり、ウイルスに対する有効な治療法を開発するために創薬アウトソーシングが重要な局面を迎えています。このため、今後2年間は短期的なブームとなり、その後は元の成長曲線に戻ると予想されます。

創薬アウトソーシング市場レポートハイライト

  • 2021年、リードの特定と候補の最適化のセグメントが市場を独占しました。創薬において最も重要なプロセスの1つです。
  • オンコロジーと抗感染症は予測期間中に最も成長率の高いセグメントの1つと予測される
  • 2021年は低分子化合物が市場を独占しました。また、このセグメントは予測期間中に高いCAGRを記録すると予測されています。ただし、生物学的製剤への重点化により、短期的には変化する可能性あり
  • 予測期間中、アジア太平洋地域が最も急速に成長することが予測される
  • 米国の製薬企業との提携に向けた政府の取り組みが成長の要因

目次

第1章 調査手法と範囲

  • 市場セグメンテーションと範囲
    • ワークフロー
    • 治療領域
    • 薬剤の種類
    • 地域範囲
    • 推定・予測のタイムライン
  • 調査手法
  • 情報調達
    • 購入したデータベース
    • GVRの内部データベース
    • 二次情報
    • 1次調査
    • 1次調査内容
  • 情報またはデータ分析
    • データ分析モデル
  • 市場の策定と検証
  • モデルの詳細
    • コモディティフロー分析(モデル1)
      • アプローチ1:コモディティフローアプローチ
    • ボリューム価格分析(モデル2)
      • アプローチ2:出来高分析
  • 二次情報一覧
  • 一次情報のリスト
  • 目的

第2章 エグゼクティブサマリー

  • 市場の見通し
  • セグメントの見通し
  • 競合考察

第3章 創薬アウトソーシング市場の変数、動向、範囲

  • 浸透と成長の見通しのマッピング
  • 業界バリューチェーン分析
    • 償還の枠組み
  • 市場力学
    • 市場促進要因分析
    • 市場抑制分析
    • 業界の課題
  • 創薬アウトソーシング市場分析ツール
    • 業界分析- ポーターズ
      • サプライヤーの力
      • 買い手の交渉力
      • 代替の脅威
      • 新規参入者の脅威
      • 競争企業間の敵対関係
    • PESTEL分析
      • 政治情勢
      • 技術情勢
      • 経済情勢
    • 主要取引と戦略的提携分析
    • 市場参入戦略

第4章 創薬アウトソーシング市場:ワークフローの推定・動向分析

  • セグメントダッシュボード
  • 定義と範囲
  • 創薬アウトソーシングの市場シェア、2021年および2030年
  • 市場規模と予測、トレンド分析、2017年から2030年までの以下の製品
    • 標的の同定とスクリーニング
    • ターゲット検証と機能情報学
    • 見込み客の特定と候補者の最適化
    • 前臨床開発
    • その他の関連ワークフロー

第5章 創薬アウトソーシング市場:治療分野の推定・動向分析

  • セグメントダッシュボード
  • 定義と範囲
  • 創薬アウトソーシングの市場シェア、2021年および2030年
  • 市場規模と予測、トレンド分析、2017年から2030年までの以下の製品
    • 呼吸器系
    • 痛みと麻酔
    • 腫瘍学
    • 眼科
    • 血液学
    • 心臓血管
    • 内分泌
    • 胃腸
    • 免疫調節
    • 抗感染症
    • 中枢神経系
    • 皮膚科
    • 泌尿生殖器系

第6章 創薬アウトソーシング市場:薬剤タイプの推定・動向分析

  • セグメントダッシュボード
  • 定義と範囲
  • 創薬アウトソーシングの市場シェア、2021年および2030年
  • 市場規模と予測、トレンド分析、2017年から2030年までの以下の製品
    • 小分子
    • 高分子(バイオ医薬品)

第7章 創薬アウトソーシング市場:地域推定・動向分析

  • 地域市場ダッシュボード
  • 地域市場シェア分析、2021年および2030年
  • 地域市場シェア、2020年
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
  • アジア太平洋地域
    • 日本
    • 中国
  • ラテンアメリカ
    • ブラジル
  • MEA
    • 南アフリカ

第8章 競合情勢

  • Recent Developments &Impact Analysis, By Key Market Participants
    • Albany Molecular Research Inc.
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • EVOTEC
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Laboratory Corporation of America Holdings
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • GenScript
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • PPD Inc
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Charles River
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • WuXi AppTec
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Merck &Co., Inc.
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Thermo Fisher Scientific Inc.
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Dalton Pharma Services
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Oncodesign
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • Jubilant Biosys
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • DiscoverX Corporation
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • QIAGEN
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
図表

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 List of Secondary Sources
  • Table 3 Global Drug Discovery Outsourcing Market, by Region 2017 - 2030 (USD Million)
  • Table 4 Global Drug Discovery Outsourcing Market, by Workflow, 2017 - 2030 (USD Million)
  • Table 5 Global Drug Discovery Outsourcing Market, by Therapeutics Area, 2017 - 2030 (USD Million)
  • Table 6 Global Drug Discovery Outsourcing Market, by Drug Type, 2017 - 2030 (USD Million)
  • Table 7 North America Drug Discovery Outsourcing Market, by Country, 2017 - 2030 (USD Million)
  • Table 8 North America Drug Discovery Outsourcing Market, by Workflow, 2017 - 2030 (USD Million)
  • Table 9 North America Drug Discovery Outsourcing Market, by Therapeutics Area, 2017 - 2030 (USD Million)
  • Table 10 North America Drug Discovery Outsourcing Market, by Drug Type, 2017 - 2030 (USD Million)
  • Table 11 U.S. Drug Discovery Outsourcing Market, by Workflow, 2017 - 2030 (USD Million)
  • Table 12 U.S. Drug Discovery Outsourcing Market, by Therapeutics Area, 2017 - 2030 (USD Million)
  • Table 13 U.S. Drug Discovery Outsourcing Market, by Drug Type, 2017 - 2030 (USD Million)
  • Table 14 Canada Drug Discovery Outsourcing Market, by Workflow, 2017 - 2030 (USD Million)
  • Table 15 Canada Drug Discovery Outsourcing Market, by Therapeutics Area, 2017 - 2030 (USD Million)
  • Table 16 Canada Drug Discovery Outsourcing Market, by Drug Type, 2017 - 2030 (USD Million)
  • Table 17 Europe Drug Discovery Outsourcing Market, by Country, 2017 - 2030 (USD Million)
  • Table 18 Europe Drug Discovery Outsourcing Market, by Workflow, 2017 - 2030 (USD Million)
  • Table 19 Europe Drug Discovery Outsourcing Market, by Therapeutics Area, 2017 - 2030 (USD Million)
  • Table 20 Europe Drug Discovery Outsourcing Market, by Drug Type, 2017 - 2030 (USD Million)
  • Table 21 U.K. Drug Discovery Outsourcing Market, by Workflow, 2017 - 2030 (USD Million)
  • Table 22 U.K. Drug Discovery Outsourcing Market, by Therapeutics Area, 2017 - 2030 (USD Million)
  • Table 23 U.K. Drug Discovery Outsourcing Market, by Drug Type, 2017 - 2030 (USD Million)
  • Table 24 Germany Drug Discovery Outsourcing Market, by Workflow, 2017 - 2030 (USD Million)
  • Table 25 Germany Drug Discovery Outsourcing Market, by Therapeutics Area, 2017 - 2030 (USD Million)
  • Table 26 Germany Drug Discovery Outsourcing Market, by Drug Type, 2017 - 2030 (USD Million)
  • Table 27 Asia Pacific Drug Discovery Outsourcing Market, by Country, 2017 - 2030 (USD Million)
  • Table 28 Asia Pacific Drug Discovery Outsourcing Market, by Workflow, 2017 - 2030 (USD Million)
  • Table 29 Asia Pacific Discovery Outsourcing Market, by Therapeutics Area, 2017 - 2030 (USD Million)
  • Table 30 Asia Pacific Drug Discovery Outsourcing Market, by Drug Type, 2017 - 2030 (USD Million)
  • Table 31 Japan Drug Discovery Outsourcing Market, by Workflow, 2017 - 2030 (USD Million)
  • Table 32 Japan Drug Discovery Outsourcing Market, by Therapeutics Area, 2017 - 2030 (USD Million)
  • Table 33 Japan Drug Discovery Outsourcing Market, by Drug Type, 2017 - 2030 (USD Million)
  • Table 34 China Drug Discovery Outsourcing Market, by Workflow, 2017 - 2030 (USD Million)
  • Table 35 China Drug Discovery Outsourcing Market, by Therapeutics Area, 2017 - 2030 (USD Million)
  • Table 36 China Drug Discovery Outsourcing Market, by Drug Type, 2017 - 2030 (USD Million)
  • Table 37 Latin America Drug Discovery Outsourcing Market, by Country, 2017 - 2030 (USD Million)
  • Table 38 Latin America Drug Discovery Outsourcing Market, by Workflow, 2017 - 2030 (USD Million)
  • Table 39 Latin America Drug Discovery Outsourcing Market, by Therapeutics Area, 2017 - 2030 (USD Million)
  • Table 40 Latin America Drug Discovery Outsourcing Market, by Drug Type, 2017 - 2030 (USD Million)
  • Table 41 Brazil Drug Discovery Outsourcing Market, by Workflow, 2017 - 2030 (USD Million)
  • Table 42 Brazil Drug Discovery Outsourcing Market, by Therapeutics Area, 2017 - 2030 (USD Million)
  • Table 43 Brazil Drug Discovery Outsourcing Market, by Drug Type, 2017 - 2030 (USD Million)
  • Table 44 MEA Drug Discovery Outsourcing Market, by Country, 2017 - 2030 (USD Million)
  • Table 45 MEA Drug Discovery Outsourcing Market, by Workflow, 2017 - 2030 (USD Million)
  • Table 46 MEA Drug Discovery Outsourcing Market, by Therapeutics Area, 2017 - 2030 (USD Million)
  • Table 47 MEA Drug Discovery Outsourcing Market, by Drug Type, 2017 - 2030 (USD Million)
  • Table 48 South Africa Drug Discovery Outsourcing Market, by Workflow, 2017 - 2030 (USD Million)
  • Table 49 South Africa Discovery Outsourcing Market, by Therapeutics Area, 2017 - 2030 (USD Million)
  • Table 50 South Africa Drug Discovery Outsourcing Market, by Drug Type, 2017 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Drug Discovery Outsourcing market: Market snapshot
  • Fig. 9 Drug Discovery Outsourcing market: Market segmentation
  • Fig. 10 Drug Discovery Outsourcing market Strategy framework
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Drug Discovery Outsourcing market driver impact
  • Fig. 14 Drug Discovery Outsourcing market restraint impact
  • Fig. 15 Drug Discovery Outsourcing market porter's five forces analysis
  • Fig. 16 Drug Discovery Outsourcing market PESTEL analysis
  • Fig. 17 Drug Discovery Outsourcing market segment dashboard
  • Fig. 18 Drug Discovery Outsourcing market: workflow movement Analysis
  • Fig. 19 Target identification & screening drug discovery outsourcing market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 20 Target validation & functional informatics drug discovery outsourcing market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 21 Lead identification & candidate optimization drug discovery outsourcing market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 22 Preclinical development drug discovery outsourcing market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 23 Other associated workflow drug discovery outsourcing market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 24 Drug Discovery Outsourcing market segment dashboard
  • Fig. 25 Respiratory system drug discovery outsourcing market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 26 Pain and anesthesia drug discovery outsourcing market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 27 Oncology drug discovery outsourcing market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 28 Ophthalmology drug discovery outsourcing market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 29 Hematology drug discovery outsourcing market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 30 Cardiovascular drug discovery outsourcing market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 31 Endocrine drug discovery outsourcing market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 32 Gastrointestinal drug discovery outsourcing market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 33 Immunomodulation drug discovery outsourcing market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 34 Anti-infective drug discovery outsourcing market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 35 Central nervous system drug discovery outsourcing market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 36 Dermatology drug discovery outsourcing market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 37 Dermatology drug discovery outsourcing market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 38 Genitourinary system drug discovery outsourcing market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 39 Global drug discovery outsourcing market: Regional movement analysis
  • Fig. 40 Global market share, by region
  • Fig. 41 North America market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 42 U.S. market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 43 Canada market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 44 Europe market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 45 U.K. market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 46 Germany market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 47 Asia Pacific market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 48 Japan market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 49 China market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 50 Latin America market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 51 Brazil market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 52 Middle East and Africa market estimates and forecast, 2017 - 2030 (USD Million)
  • Fig. 53 South Africa market estimates and forecast, 2017 - 2030 (USD Million)
目次
Product Code: GVR-2-68038-392-8

Drug Discovery Outsourcing Market Growth & Trends:

The global drug discovery outsourcing market size is expected to reach USD 6.3 billion by 2030 at a CAGR of 7.4% over the forecast period, according to a new report by Grand View Research, Inc. The COVID-19 pandemic has brought pharmaceutical companies in limelight. Drug discovery is a costly and lengthy process. This has urged pharmaceutical and biotech companies to opt for outsourcing their research activities to academic and private Contract Research Organizations (CROs). Rising partnerships between public or private entities accelerate drug discovery processes, which, in turn, increase the global demand for outsourcing services for drug discovery.

This scenario is expected to sustain post the covid implications as well. A rise in cases of chronic diseases has urged companies to develop medicines that extend life expectancy. According to the United Nations, people aged 65 years between 2015 and 2020 are expected to live an additional 17 years. Some of the key therapeutic areas where companies are actively involved in outsourcing include oncology, cardiovascular, and anti-infectives. In November 2020, AstraZeneca collaborated with 9 of the foremost oncology medical centers to expedite research in some of the hardest-to-treat cancers. The company will be funding clinical and non-clinical research proposals from members of this network.

The COVID-19 pandemic has demonstrated the value of drug discovery and development. People across the world are waiting for a vaccine while several companies are proactively involved in developing an effective vaccine to combat COVID-19. Pfizer Inc. and BioNTech SE received first approval for the vaccine following a worldwide Phase 3 trial of a potential strain to combat the virus. As for clinical trials, many of them are halted, while some are functional by adopting remote monitoring technologies. Thus, the pandemic has brought the pharmaceutical industry to center stage with drug discovery outsourcing becoming a key aspect to develop effective treatments against the virus. This is expected to boost the market revenue for the next 2 years i.e. a short-term boom, after which it shall regain its original growth curve.

Drug Discovery Outsourcing Market Report Highlights:

  • In 2021, the lead identification & candidate optimization segment dominated the market. It is one of the most critical processes in drug discovery
  • Oncology and anti-infective are projected to be among the fastest-growing segments during the forecast period
  • Small molecules dominated the market in 2021. The segment is also projected to register a high CAGR during the forecast period. This, however, may change in the short term with higher emphasis on biologics
  • Asia Pacific is projected to be the fastest-growing regional market during the forecast period
  • The growth can be attributed to the government initiatives to forge alliances with U.S. pharmaceutical companies

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Workflow
    • 1.1.2. Therapeutics Area
    • 1.1.3. Drug Type
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1:
    • 1.9.2. Objective 2:
    • 1.9.3. Objective 3:
    • 1.9.4. Objective 4:

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Drug Discovery Outsourcing Market Variables, Trends & Scope

  • 3.1. Penetration & Growth Prospect Mapping
  • 3.2. Industry Value Chain Analysis
    • 3.2.1. Reimbursement framework
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
    • 3.3.3. Industry challenges
  • 3.4. Drug Discovery Outsourcing Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape
    • 3.4.3. Major Deals & Strategic Alliances Analysis
    • 3.4.4. Market Entry Strategies

Chapter 4. Drug Discovery Outsourcing Market: Workflow Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Definitions and Scope
  • 4.3. Drug Discovery Outsourcing Market Share, 2021 & 2030
  • 4.4. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
    • 4.4.1. Target Identification & Screening
    • 4.4.2. Target Validation & Functional Informatics
    • 4.4.3. Lead Identification & Candidate Optimization
    • 4.4.4. Preclinical Development
    • 4.4.5. Other Associated Workflow

Chapter 5. Drug Discovery Outsourcing Market: Therapeutics Area Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Definitions and Scope
  • 5.3. Drug Discovery Outsourcing Market Share, 2021 & 2030
  • 5.4. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
    • 5.4.1. Respiratory System
    • 5.4.2. Pain and Anesthesia
    • 5.4.3. Oncology
    • 5.4.4. Ophthalmology
    • 5.4.5. Hematology
    • 5.4.6. Cardiovascular
    • 5.4.7. Endocrine
    • 5.4.8. Gastrointestinal
    • 5.4.9. Immunomodulation
    • 5.4.10. Anti-Infective
    • 5.4.11. Central Nervous System
    • 5.4.12. Dermatology
    • 5.4.13. Genitourinary System

Chapter 6. Drug Discovery Outsourcing Market: Drug Type Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Definitions and Scope
  • 6.3. Drug Discovery Outsourcing Market Share, 2021 & 2030
  • 6.4. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
    • 6.4.1. Small Molecules
    • 6.4.2. Large Molecules (Biopharmaceuticals)

Chapter 7. Drug Discovery Outsourcing Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2021 & 2030
  • 7.3. Regional Market Share, 2020
  • 7.4. North America
    • 7.4.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Market estimates and forecast, 2017 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.5.2. U.K.
      • 7.5.2.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Market estimates and forecast, 2017 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Market estimates and forecast, 2017 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Market estimates and forecast, 2017 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. Market estimates and forecast, 2017 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Market estimates and forecast, 2017 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
    • 8.1.1. Albany Molecular Research Inc.
      • 8.1.1.1. Company overview
      • 8.1.1.2. Financial performance
      • 8.1.1.3. Product benchmarking
      • 8.1.1.4. Strategic initiatives
    • 8.1.2. EVOTEC
      • 8.1.2.1. Company overview
      • 8.1.2.2. Financial performance
      • 8.1.2.3. Product benchmarking
      • 8.1.2.4. Strategic initiatives
    • 8.1.3. Laboratory Corporation of America Holdings
      • 8.1.3.1. Company overview
      • 8.1.3.2. Financial performance
      • 8.1.3.3. Product benchmarking
      • 8.1.3.4. Strategic initiatives
    • 8.1.4. GenScript
      • 8.1.4.1. Company overview
      • 8.1.4.2. Financial performance
      • 8.1.4.3. Product benchmarking
      • 8.1.4.4. Strategic initiatives
    • 8.1.5. PPD Inc
      • 8.1.5.1. Company overview
      • 8.1.5.2. Financial performance
      • 8.1.5.3. Product benchmarking
      • 8.1.5.4. Strategic initiatives
    • 8.1.6. Charles River
      • 8.1.6.1. Company overview
      • 8.1.6.2. Financial performance
      • 8.1.6.3. Product benchmarking
      • 8.1.6.4. Strategic initiatives
    • 8.1.7. WuXi AppTec
      • 8.1.7.1. Company overview
      • 8.1.7.2. Financial performance
      • 8.1.7.3. Product benchmarking
      • 8.1.7.4. Strategic initiatives
    • 8.1.8. Merck & Co., Inc.
      • 8.1.8.1. Company overview
      • 8.1.8.2. Financial performance
      • 8.1.8.3. Product benchmarking
      • 8.1.8.4. Strategic initiatives
    • 8.1.9. Thermo Fisher Scientific Inc.
      • 8.1.9.1. Company overview
      • 8.1.9.2. Financial performance
      • 8.1.9.3. Product benchmarking
      • 8.1.9.4. Strategic initiatives
    • 8.1.10. Dalton Pharma Services
      • 8.1.10.1. Company overview
      • 8.1.10.2. Financial performance
      • 8.1.10.3. Product benchmarking
      • 8.1.10.4. Strategic initiatives
    • 8.1.11. Oncodesign
      • 8.1.11.1. Company overview
      • 8.1.11.2. Financial performance
      • 8.1.11.3. Product benchmarking
      • 8.1.11.4. Strategic initiatives
    • 8.1.12. Jubilant Biosys
      • 8.1.12.1. Company overview
      • 8.1.12.2. Financial performance
      • 8.1.12.3. Product benchmarking
      • 8.1.12.4. Strategic initiatives
    • 8.1.13. DiscoverX Corporation
      • 8.1.13.1. Company overview
      • 8.1.13.2. Financial performance
      • 8.1.13.3. Product benchmarking
      • 8.1.13.4. Strategic initiatives
    • 8.1.14. QIAGEN
      • 8.1.14.1. Company overview
      • 8.1.14.2. Financial performance
      • 8.1.14.3. Product benchmarking
      • 8.1.14.4. Strategic initiatives